Mental and Behavioral Health

Suicides among health care professionals are estimated to occur at a higher rate than in the general public.

According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023.

Researchers hope a new study will alleviate patients and clinicians fear of prescribing stimulants for children with ADHD.

Centanafadine is a serotonin-norepinephrine-dopamine triple reuptake inhibitor.

The incidence and prevalence of TRD is explored.

Megan Maroney, PharmD, BCPP, leads a discussion about the treatment landscape of TRD.

Pharmacogenetic testing and therapeutic drug monitoring are feasible in the inpatient psychiatric treatment setting.

Survey respondents indicated a lack of comfort around recommending psilocybin therapy to patients.

How can current Alzheimer disease treatments be used to best treat patients living with the disease?

There was a lower probability of initiating psycholeptics and experiencing postpartum psychiatric emergencies in study patients who continued using antidepressants

Developing innovative solutions for women with depression, accounting for differences in gender and sex, are critically important

A recent CDC report detailed the increased rates of sadness and violence among teenage girls.

United States leaders work together to create bipartisan solutions for the youth mental health crisis.

The relationship between dermatology and social media was analyzed in a poster presentation during SBS 2023 in Miami, Florida.

Zuranolone, a fast-acting neuroactive steroid that can take effect in 14 days, has been assigned a PDUFA action date of Aug. 5, 2023 by the FDA. It can be used to treat patients with major depressive disorder and postpartum depression.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

There may not be a diagnosis for ‘New Year Depression,’ but about 10% to 20% of individuals in the US may get a milder form of these winter blues.

A recent study found a rise in the prevalence of antipsychotic prescriptions among pediatric patients and noted which antipsychotics were most commonly used for specific indications.

A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.

Pharmacists can use a variety of tools to foster resilience and prevent burnout.

A recent study highlights the significant frequency of the adverse effect.

Pradaxa (dabigatran) and Coumadin (warfarin) came out even in this randomized study. The Brazilian researchers who conducted the study said one explanation for the result is that use of Coumadin was exceptionally well managed because the patients were enrolled a study.

When dealing with marginalized and underserved populations, it is important to understand barriers to care and why they exist.

With increasing use of telehealth, patients need access to resources that let them get the most out of the experience.

Social support and education may be the solution.

Online portals are accessible via tablet or computer and can streamline the mental health screening process.

Cost savings were not associated with an increase in adverse drug events.

Low-income subsidies can eliminate much of the out-of-pocket costs that patients must pay.

We may be one step closer to nonprescription naloxone.